Clinical Trial Update: Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled adaptive trial of intrathecally administered autologous mesenchymal stem cells for Multiple System Atrophy,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• Autologous Mesenchymal Stem Cells (intrathecal) (mesenchymal stem cells)

Snippet

Sponsor: Mayo Clinic | Conditions: Multiple System Atrophy | Phase 2 | Status: ACTIVE_NOT_RECRUITING